MedDRA preferred term

Psychomotor hyperactivity: adverse event reports recording this term

16,255 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

16,255
reports recording the term: 0.1% of all reports; 609
reports, 12 months to June 2026: 607 in the 12 months before; 60.7%
marked serious by the reporter: 57.4% across all reports; 2.2%
record death among outcomes, as reported: 9.1% across all reports

"Psychomotor hyperactivity" is a MedDRA preferred term recorded in 16,255 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

609 reports recorded it in the 12 months to June 2026, close to the 607 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 60.7% are marked serious, 2.2% include death among the outcomes and 27.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Daytrana, Strattera and Olanzapine. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Daytrana	Central nervous system stimulant	411	3%
Strattera	Norepinephrine reuptake inhibitor	352	2.2%
Olanzapine	Atypical antipsychotic	317	0.7%
Quetiapine	Atypical antipsychotic	302	0.6%
Sertraline	Serotonin reuptake inhibitor	258	0.6%
Abilify	Atypical antipsychotic	254	0.5%
Risperidone	Atypical antipsychotic	254	0.6%
Vyvanse	Central nervous system stimulant	252	1.4%
Aripiprazole	Atypical antipsychotic	248	0.8%
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	198	0.4%
Levetiracetam	—	198	0.4%
Seroquel	Atypical antipsychotic	197	0.4%
Lamotrigine	Anti-epileptic agent	192	0.4%
Montelukast	Leukotriene receptor antagonist	191	1.5%
Lorazepam	Benzodiazepine	170	0.5%
Gabapentin	Anti-epileptic agent	168	0.2%
Lyrica	—	163	0.1%
Mirtazapine	—	163	0.5%
Haloperidol	Typical antipsychotic	162	1.1%
Prednisone	Corticosteroid	161	0.1%
Chantix	Partial cholinergic nicotinic agonist	160	0.2%
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	153	0.5%
Diazepam	Benzodiazepine	144	0.4%
Alprazolam	Benzodiazepine	143	0.3%
Concerta	Central nervous system stimulant	142	1.3%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Atypical antipsychotic	2,468	0.4%	0.2%
Central nervous system stimulant	1,326	1.2%	0.6%
Serotonin reuptake inhibitor	1,098	0.4%	0.3%
Anti-epileptic agent	927	0.3%	0.2%
Benzodiazepine	904	0.4%	0.3%
Corticosteroid	761	0.1%	0%
Serotonin and norepinephrine reuptake inhibitor	702	0.4%	0.4%
Opioid agonist	415	0%	0%
Leukotriene receptor antagonist	396	1%	1.1%
Norepinephrine reuptake inhibitor	396	1.9%	1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 21.4%227

2 to 1113.3%2,160

12 to 174.1%668

18 to 4416.3%2,656

45 to 6418%2,923

65 to 747.4%1,195

75 and over6.6%1,068

Age not given33%5,358

Patient sex

Female47.4%7,699

Male42.9%6,977

Not given9.7%1,579

Grey bar: all 20,646,523 reports in the database. 55.7% of these reports give the United States as the country.

Questions about "Psychomotor hyperactivity"

What does "Psychomotor hyperactivity" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record psychomotor hyperactivity?

16,255 reports through June 2026 (0.1% of all reports), 609 of them in the latest 12 months.

Which drugs appear most often in these reports?

Daytrana (411), Strattera (352), Olanzapine (317), Quetiapine (302) and Sertraline (258). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.